Mid-teens % decline





Adjusted Free Cash Flow (Non-IFRS)





650.0-750.0





---





Annual Dividend per Share (Yen)





204





---








Pipeline Achievements Set the Stage for Future Growth
Our three leading late-stage assets are positioned for regulatory approvals in the U.S. and other geographies in FY2026-2027. We expect this will be a pivotal period for launches and investment with clear near-term wins and proof points over the next 12–24 months.

oveporexton:


Oveporexton is potentially a first-of-its-kind orexin agonist designed to address the underlying orexin deficiency that ca
=*=*=*=*=*=
当前为第6/23页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页